골관절염 치료제 시장 : 치료 유형, 병기, 투여 경로, 최종사용자, 유통 채널별 - 세계 예측(2025-2030년)

The Osteoarthritis Therapeutics Market was valued at USD 5.17 billion in 2024 and is projected to grow to USD 5.55 billion in 2025, with a CAGR of 7.49%, reaching USD 7.98 billion by 2030.

Osteoarthritis remains one of the most commonly diagnosed chronic musculoskeletal conditions worldwide, posing significant challenges for patient quality of life and healthcare systems alike. Recent advances in therapeutics have yielded promising results, altering not only treatment methodologies but also the underlying market dynamics. Current research and clinical practices highlight a rapidly evolving landscape driven by innovations across various treatment modalities. The importance of timely diagnosis, combined with evolving patient preferences and clinical evidences, has opened new avenues for elevating patient care standards. This executive summary brings together the latest observations, comprehensive segmentation analysis, key regional insights, and the influence of major industry players to help decision-makers and industry experts navigate the complex environment of osteoarthritis treatment. Through a detailed exploration of innovative therapeutic strategies, market segmentation intricacies, and evolving regional trends, this overview provides a robust understanding of current trends while laying the groundwork for future growth opportunities. The discussion also sheds light on the competitive landscape and the proactive measures adopted by leading companies, ensuring that the reader obtains a complete picture of the market's current and future orientations.

Transformative Shifts in the Osteoarthritis Therapeutics Landscape

Over recent years, the landscape of osteoarthritis therapeutics has undergone transformative shifts that have redefined conventional approaches to treatment. Emerging trends in scientific research combined with a shift in regulatory frameworks have accelerated the pace of innovation and reassessment of treatment protocols. Advances in biotech and pharmaceutical research have optimized drug delivery, with new formulations targeting inflammation and pain management more effectively than traditional methods. Furthermore, the integration of digital health tools and telemedicine has widened patient access to specialized care, enabling better monitoring and personalized treatment plans that adapt to individual patient needs. The advent of novel surgical techniques has also contributed significantly to improved treatment outcomes, reflecting a holistic approach that balances conservative measures with interventional procedures. As patient demographics evolve and the incidence of comorbidities rises, clinical preferences are shifting towards integrated treatment plans that combine complementary therapies with conventional interventions. This shift is bolstered by emerging evidence that supports multi-modal interventions, thereby improving patient adherence and enhancing therapeutic efficacy. Overall, these developments signal a move toward a more patient-centric therapeutic model that integrates technology, innovation, and clinical expertise, ensuring that treatments remain safe, effective, and adaptive to individualized patient profiles.

Key Segmentation Insights in Osteoarthritis Therapeutics

An in-depth analysis of market segmentation reveals a multifaceted approach to understanding and addressing patient needs in osteoarthritis therapeutics. The market is scrutinized based on multiple parameters, beginning with treatment type. Here, the landscape is divided into complementary therapies, drug therapy, physical therapy, and surgical intervention. Complementary therapies have grown increasingly significant, with practices such as acupuncture, massage therapy, and nutritional supplements being evaluated for their potential to enhance overall well-being alongside conventional treatments. In contrast, drug therapies have been dissected further into treatments involving corticosteroid injections, hyaluronic acid injections, non-steroidal anti-inflammatory drugs, and opioids, each presenting distinct advantages and challenges that influence patient adherence and outcomes. Surgical interventions follow a similarly detailed breakdown, separating arthroscopy from joint replacement and osteotomy. Notably, osteotomy is further elaborated by clinical focus on femoral and tibial variations, highlighting the nuanced approach necessary for different patient demographics. Complementing these categories, segmentation based on disease stage is classified into advanced, early, and moderate stages, reflecting the dynamic clinical approaches from preventive care to aggressive intervention. Moreover, considerations regarding the route of administration include injectable, oral, topical, and transdermal formulations, each chosen based on patient compliance and therapeutic outcome. Analysis is also extended to end-user segmentation covering clinics, hospitals, and rehabilitation centers, and further bifurcated by distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies. This multifaceted segmentation framework validates the need for a more specialized focus as well as integrated cross-modal strategies in clinical practice, underscoring the varied patient expectations and optimizing treatment approaches to achieve better clinical and operational outcomes.

Based on Treatment Type, market is studied across Complementary Therapies, Drug Therapy, Physical Therapy, and Surgery. The Complementary Therapies is further studied across Acupuncture, Massage Therapy, and Nutritional Supplements. The Drug Therapy is further studied across Corticosteroid Injections, Hyaluronic Acid Injections, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Opioids. The Surgery is further studied across Arthroscopy, Joint Replacement, and Osteotomy. The Osteotomy is further studied across Femoral Osteotomy and Tibial Osteotomy.

Based on Disease Stage, market is studied across Advanced Stage, Early Stage, and Moderate Stage.

Based on Route of Administration, market is studied across Injectable, Oral, Topical, and Transdermal.

Based on End-User, market is studied across Clinics, Hospitals, and Rehabilitation Centers.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights in the Global Osteoarthritis Therapeutics Market

The global osteoarthritis therapeutics market exhibits dynamic regional patterns that reflect distinct socio-economic conditions, regulatory environments, and healthcare infrastructure maturity. In the Americas, robust investments in healthcare innovation coupled with a high prevalence of osteoarthritis have driven significant research and market growth. Here, advancements in clinical trial methodologies and rapid adoption of digital health technologies have laid the foundation for improved patient management and intervention strategies. In parallel, the combined region of Europe, Middle East, and Africa showcases a diverse therapeutic landscape where historical clinical practices intersect with modern therapeutic interventions. European markets reflect a favorable regulatory environment that promotes rapid integration of breakthrough treatments, while the Middle East and Africa display an increasing focus on accessibility and cost-effective solutions owing to shifting demographics and rising patient populations. Across Asia-Pacific, market dynamics are propelled by a significant increase in healthcare expenditures and a prominent shift towards modern treatment modalities. Rapid urbanization and growing patient awareness have catalyzed the demand for innovative therapeutic interventions that blend traditional practices with cutting-edge pharmaceutical developments. These regional insights indicate that while each area is characterized by unique challenges, the overall market trend is toward bridging accessibility gaps, enhancing therapeutic efficacy, and aligning treatment protocols with patient-specific needs. Such an integrated understanding of regional trends can serve as a key determinant in shaping strategic decisions for stakeholders operating in this competitive landscape.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Shaping Osteoarthritis Therapeutics Market Dynamics

The current market environment is influenced significantly by a range of leading companies that are investing heavily in research, development, and marketing initiatives aimed at improving osteoarthritis outcomes. Industry stalwarts such as AbbVie Inc. and Amgen Inc. leverage extensive research pipelines to introduce novel drug therapies while companies like Anika Therapeutics, Inc. and AstraZeneca PLC capitalize on innovative techniques to optimize treatment efficacy. Tradition-bound pharmaceutical giants such as Bayer AG and Boehringer Ingelheim International GmbH have consistently provided robust treatment options through both agent development and technology integration. The competitive landscape is further enriched by firms such as Cipla Ltd. and Doron Therapeutics, alongside globally recognized entities including Eli Lilly and Company and Endo International plc, which emphasize advanced drug delivery systems and minimally invasive surgical techniques. Smaller but highly innovative companies such as Ferring B.V. and Fidia Farmaceutici S.p.A have also made notable contributions by focusing on niche areas of complementary treatment approaches. Capitalizing on a balanced portfolio, industry leaders such as GlaxoSmithKline PLC, Hanmi Pharm. Co., Ltd., and Hikma Pharmaceuticals PLC have introduced a range of therapies that address diverse patient needs, while Johnson & Johnson Services Inc. and Kitov Pharmaceuticals Ltd. drive market momentum through patient-centric innovation. Notably, organizations like Mallinckrodt Pharmaceuticals, Merck & Co., Pacira BioSciences, Inc., and Pfizer Inc. have strategically positioned themselves to leverage emerging trends and optimize distribution networks. Meanwhile, the presence of Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., UCB S.A., and Viatris Inc. highlights the importance of a diversified approach that is responsive to the rapidly evolving demands of the global osteoarthritis market. The combined efforts of these companies not only reinforce their individual commitments to advancing therapeutic interventions but also collectively contribute to the overarching momentum propelling the industry forward.

The report delves into recent significant developments in the Osteoarthritis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Anika Therapeutics, Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Ltd., Doron Therapeutics, Eli Lilly and Company, Endo International plc, Ferring B.V., Fidia Farmaceutici S.p.A, GlaxoSmithKline PLC, Hanmi Pharm. Co., Ltd., Hikma Pharmaceuticals PLC, Johnson & Johnson Services Inc., Kitov Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Merck & Co., Pacira BioSciences, Inc., Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., UCB S.A., and Viatris Inc.. Actionable Recommendations for Decision-Makers in Osteoarthritis Therapeutics

Industry leaders are encouraged to adopt a forward-thinking approach centered on technological innovation, strategic partnerships, and personalized patient care. To remain competitive, decision-makers should focus on enhancing research and development endeavors that integrate comprehensive clinical insights with state-of-the-art treatment modalities. Emphasis on multi-modal treatments, which include a blend of complementary therapies, pharmacological interventions, and minimally invasive surgical procedures, will likely yield improved patient outcomes. Additionally, adapting to evolving regulatory standards and investing in robust digital infrastructure can streamline patient management processes and improve adherence to treatment protocols. It is advisable for industry experts to continuously monitor segmented market trends-ranging from disease stage to end-user preferences-and tailor their product portfolios accordingly to maximize market penetration. Strengthening collaborations with key regional players and optimizing distribution channels will further enhance market reach and patient accessibility. Companies are also advised to harness the potential of partnership opportunities across geographies, investing strategically in both emerging and established markets to maintain product relevancy. By staying attuned to the needs of clinicians and patients alike, decision-makers can implement actionable strategies that drive both clinical excellence and sustainable market growth.

Conclusion: Summarizing Key Insights for Future Growth

In summary, the evolving landscape of osteoarthritis therapeutics is characterized by rapid innovation, targeted segmentation, and dynamic regional growth patterns, all of which are influenced by pioneering efforts from leading companies. The integration of advanced treatment modalities, coupled with a strong emphasis on patient-centric care and strategic market segmentation, has laid a sound foundation for sustained industry evolution. As the market continues to mature, stakeholders must remain agile, adapting to technological advances and shifting clinical paradigms. The insights outlined herein offer a comprehensive roadmap for navigating the complexities of this competitive field, underscoring the need for continuous innovation, strategic regional engagement, and responsive operational strategies. In the face of emerging trends and heightened competition, aligning product offerings with evolving patient demands will be crucial in driving future growth and ensuring long-term success in osteoarthritis therapeutics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising aging population leading to heightened incidence of joint degeneration and related complications
    • 5.1.1.2. Increasing obesity rates among people globally
    • 5.1.1.3. Growing patient awareness and proactive healthcare initiatives
  • 5.1.2. Restraints
    • 5.1.2.1. High initial cost of drug development and clinical trials
  • 5.1.3. Opportunities
    • 5.1.3.1. Developing cell-based therapies and regenerative medicine strategies to provide targeted treatments
    • 5.1.3.2. Leveraging digital health technologies and remote patient monitoring to enhance osteoarthritis treatment adherence
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with product recall of osteoarthritis therapeutics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type : Growing demand for complementary therapies in osteoarthritis therapeutics
  • 5.2.2. End-User : High preference for clinics by patients for osteoarthritis management
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Osteoarthritis Therapeutics Market, by Treatment Type

• 6.1. Introduction
• 6.2. Complementary Therapies
  • 6.2.1. Acupuncture
  • 6.2.2. Massage Therapy
  • 6.2.3. Nutritional Supplements
• 6.3. Drug Therapy
  • 6.3.1. Corticosteroid Injections
  • 6.3.2. Hyaluronic Acid Injections
  • 6.3.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.3.4. Opioids
• 6.4. Physical Therapy
• 6.5. Surgery
  • 6.5.1. Arthroscopy
  • 6.5.2. Joint Replacement
  • 6.5.3. Osteotomy
    • 6.5.3.1. Femoral Osteotomy
    • 6.5.3.2. Tibial Osteotomy

7. Osteoarthritis Therapeutics Market, by Disease Stage

• 7.1. Introduction
• 7.2. Advanced Stage
• 7.3. Early Stage
• 7.4. Moderate Stage

8. Osteoarthritis Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral
• 8.4. Topical
• 8.5. Transdermal

9. Osteoarthritis Therapeutics Market, by End-User

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Hospitals
• 9.4. Rehabilitation Centers

10. Osteoarthritis Therapeutics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Osteoarthritis Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Osteoarthritis Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Osteoarthritis Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Relation partners with GSK to leverage Lab-in-the-Loop, multi-omics, and machine learning for accelerating innovative therapeutics in osteoarthritis and fibrotic diseases
  • 14.3.2. Doron Therapeutics secures USD 11 million Series A funding to fast-track phase 3 clinical studies of MOTYS as a regenerative non-surgical medicine in osteoarthritis therapy
  • 14.3.3. Genascence's GNSC-001 gene therapy gains FDA fast track designation to enhance knee osteoarthritis treatment development
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Anika Therapeutics, Inc.
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. Boehringer Ingelheim International GmbH
• 7. Cipla Ltd.
• 8. Doron Therapeutics
• 9. Eli Lilly and Company
• 10. Endo International plc
• 11. Ferring B.V.
• 12. Fidia Farmaceutici S.p.A
• 13. GlaxoSmithKline PLC
• 14. Hanmi Pharm. Co., Ltd.
• 15. Hikma Pharmaceuticals PLC
• 16. Johnson & Johnson Services Inc.
• 17. Kitov Pharmaceuticals Ltd.
• 18. Mallinckrodt Pharmaceuticals
• 19. Merck & Co.
• 20. Pacira BioSciences, Inc.
• 21. Pfizer Inc.
• 22. Sanofi S.A.
• 23. Sun Pharmaceutical Industries Ltd.
• 24. Takeda Pharmaceutical Company
• 25. Teva Pharmaceutical Industries Ltd.
• 26. UCB S.A.
• 27. Viatris Inc.